Dominique Tersago

Technik-/Wissenschafts-/F&E-Leiter bei CANTARGIA AB

Vermögen: - $ am 30.04.2024

62 Jahre

Health Technology

Consumer Services

Aktive Positionen von Dominique Tersago

Unternehmen	Position	Beginn	Ende
CANTARGIA AB	Technik-/Wissenschafts-/F&E-Leiter	01.08.2022	-

Unternehmen	Position	Beginn	Ende
Exevir Bio BV Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium.	Technik-/Wissenschafts-/F&E-Leiter	01.07.2020	01.07.2022
Highlight Therapeutics SL Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain.	Technik-/Wissenschafts-/F&E-Leiter	01.04.2017	01.03.2020
ABLYNX	Technik-/Wissenschafts-/F&E-Leiter	01.07.2013	01.11.2015

University of Antwerp

Doctorate Degree

International

Operativ

Chief Tech/Sci/R&D Officer	4
Doctorate Degree	1

Sektoral

Health Technology	5
Consumer Services	2

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	1
CANTARGIA AB	Health Technology

Private Unternehmen	3
Ablynx NV Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium.	Health Technology
Highlight Therapeutics SL Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain.	Health Technology
Exevir Bio BV Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium.	Health Technology